patient survey

The Canadian Psoriasis Network and the Canadian Association of Psoriasis Patients are looking for patient perspectives to help decision-makers learn more about psoriasis and patient experiences with deucravacitinib for the treatment of moderate to severe plaque psoriasis. Deucravacitinib will be under review for a public drug coverage recommendation and patient input into the process is a key part of the evaluation. These submissions inform treatment recommendations to the CADTH Common Drug Review (CDR) and other health technology reviews in Canada.

If you are interested in providing your feedback based on your experience with plaque psoriasis, please find the survey here: